Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in IMMUNOME INC as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.7% beneficial ownership stake in Blackbaud, Inc. as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.8% passive ownership stake in Globus Medical, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, confirming its beneficial ownership of 5.8% of Amdocs Limited's Ordinary Shares as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a beneficial ownership of 6.1% in Zai Lab Ltd's American Depositary Shares as of December 31, 2024.

Janus Henderson Group PLC has filed an amendment to its Schedule 13G, disclosing a 6.1% passive beneficial ownership stake in ARAMARK common stock as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in CARGO Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc and its affiliate Janus Henderson Venture Fund have disclosed a combined beneficial ownership of 6.5% in ASURE SOFTWARE INC common stock as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 6.5% beneficial ownership stake in Sensata Technologies Holding PLC as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 6.7% passive beneficial ownership stake in SS&C Technologies Holdings, Inc. as of December 31, 2024.

Janus Henderson Group PLC, a global asset manager, has filed an amended Schedule 13G disclosing a beneficial ownership of 6.8% in IDEAYA Biosciences, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, disclosing a continued beneficial ownership of 6.8% in Flex Ltd. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 6.9% beneficial ownership stake in Biohaven Ltd. as of December 31, 2024, held for investment purposes.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a 7.3% beneficial ownership stake in Dyne Therapeutics Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 7.3% in Structure Therapeutics Inc.'s American Depositary Shares as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 7.4% in OSI Systems, Inc. as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 8.2% of Ziff Davis, Inc.'s common stock as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 8.5% of Vaxcyte Inc.'s common stock as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 8.9% in Lantheus Holdings, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of December 31, 2024.

Janus Henderson Group PLC and its affiliate, Janus Henderson Enterprise Fund, have disclosed significant beneficial ownership stakes in ICU Medical, Inc. through a Schedule 13G filing.

Janus Henderson Group plc has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Madrigal Pharmaceuticals, Inc. as of December 31, 2024.

Janus Henderson Group plc, through its various entities, has disclosed a 10.2% beneficial ownership stake in WEX Inc. common stock as of December 31, 2024, according to its latest Schedule 13G/A filing.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 6.5% in Liberty Media Corporation's Series C Liberty Formula One Common Stock as of December 31, 2024.

Janus Henderson Group plc and its affiliate have reported a combined beneficial ownership of 11.0% in Mereo BioPharma Group plc's American Depositary Shares as of December 31, 2024.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 11.3% of Teleflex Incorporated's common stock as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, revealing a 12.0% beneficial ownership stake in Soleno Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc, a global asset manager, has filed an amended Schedule 13G, reporting a 12.1% passive beneficial ownership stake in Cimpress plc as of December 31, 2024.

Janus Henderson Group plc and its affiliates have disclosed a beneficial ownership of 13.1% of Lexeo Therapeutics, Inc.'s common stock as of December 31, 2024, through a Schedule 13G Amendment No. 3 filing.

Janus Henderson Group PLC and its affiliates have disclosed a passive beneficial ownership of 14.6% in Avadel Pharmaceuticals PLC, primarily through its various investment entities.